Spinal chemo and immunotherapy for recurrent high-grade glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 13 years old.
- You must have a confirmed diagnosis of a high-grade glioma (like glioblastoma) that has returned after prior treatment with radiation (and, if applicable, temozolomide).
- You must have a tumor that can be seen on an MRI scan and meets specific size requirements.
- You must be on a stable or decreasing dose of steroids for at least 7 days before starting the trial.
- You must have adequate organ and blood cell function, as determined by standard lab tests.
- You cannot have active autoimmune disease, active infections, or a history of lung inflammation (pneumonitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a chemotherapy drug (thiotepa) directly into the spinal fluid for people with a newly diagnosed glioblastoma that has spread to the brain's lining or ventricles. It aims to see if this extra treatment can help control the cancer.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.